Top-News

Citius Oncology Aktie News

Aktie
WKN:  A40K7E ISIN:  US17331Y1091 US-Symbol:  CTOR Branche:  Pharmazeutika Land:  USA
1,10 $
-0,01 $
-0,90%
0,9449 € 20:50:45 Uhr
Depot/Watchlist
Marktkapitalisierung *
76,96 Mio. €
Streubesitz
10,41%
KGV
-6,15
Index-Zuordnung
-

Citius Oncology News

08.07.25 - PR Newswire
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention PR Newswire
26.06.25 - PR Newswire
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? PR Newswire
26.06.25 - PR Newswire
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? PR Newswire
17.06.25 - PR Newswire
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025 PR Newswire
12.06.25 - PR Newswire
After Major Oncology Conference, All Eyes Turn to Industry Innovation
After Major Oncology Conference, All Eyes Turn to Industry Innovation PR Newswire
12.06.25 - PR Newswire
After Major Oncology Conference, All Eyes Turn to Industry Innovation
After Major Oncology Conference, All Eyes Turn to Industry Innovation PR Newswire
09.06.25 - PR Newswire
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health PR Newswire
14.05.25 - PR Newswire
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update PR Newswire
14.02.25 - PR Newswire
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update PR Newswire
06.02.25 - PR Newswire
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services PR Newswire
07.01.25 - PR Newswire
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 PR Newswire
06.01.25 - PR Newswire
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives PR Newswire
27.12.24 - PR Newswire
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update PR Newswire
27.12.24 - PR Newswire
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +0,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »